Lubiprostone is approved for treating several specific conditions related to constipation:
- Long-lasting (chronic) constipation in adults.
- Opioid-induced constipation (OIC) in certain adult patients with chronic, non-cancer pain, provided their opioid dosage is stable.
- Irritable Bowel Syndrome with Constipation (IBS-C), specifically in women whose primary symptom is constipation.
The medication works by increasing fluid secretion in the bowels, easing stool passage and relieving constipation symptoms.
Contraindications
Should not be used in patients with known or suspected bowel obstruction or severe diarrhea.
Allergies: Patients must disclose any history of unusual or allergic reactions to this medicine or other substances.
Liver Disease: Use with caution in patients with moderate to severe liver disease, as the medicine’s effects may be increased.
Pediatric Use: Safety and efficacy have not been established in the pediatric population.
Geriatric Use: No specific geriatric-specific problems have been identified that would limit its use in the elderly.
Pregnancy/Breastfeeding: Potential benefits must be weighed against potential risks; adequate studies in women are lacking.
InteractionsPatients should discuss all other prescription, OTC, food, alcohol, or tobacco interactions with a healthcare professional.

